

## PRESS RELEASE

Date 28 April 2016  
Contact Investor Relations: Julien Vignot, Head Investor Relations, Galenica Group  
Media Relations: Christina Hertig, Head Corporate Communications, Galenica Group  
Subject 2016 Annual General Meeting of Galenica Ltd.

### **88<sup>th</sup> Annual General Meeting of Galenica Ltd.: Shareholders approve all proposals submitted by the Board of Directors**

**At the 88<sup>th</sup> Annual General Meeting of Galenica Ltd. in Bern, shareholders approved all of the proposals submitted by the Board of Directors. The Annual General Meeting was attended by 386 shareholders, representing a total of 53% of the registered voting shares of Galenica Ltd.**

The shareholders voted in favour of the proposals put forward by the Board of Directors on all items on the agenda: The Annual General Meeting approved the Annual Report and the 2015 Annual Financial Statements of Galenica Ltd. as well as the Consolidated Financial Statements of the Galenica Group for 2015 and discharged the members of the Board of Directors and the Corporate Executive Committee from liability for their activities in 2015. The Annual General Meeting also approved the proposal to renew the approved capital for a further two years.

Also approved was the dividend of CHF 18.00 (+20.0%, prior year: CHF 15.00) proposed by the Board of Directors, which will be paid to shareholders on 6 May 2016.

#### **Remuneration Report 2015 and total remuneration for financial year 2017**

The Remuneration Report was again submitted to shareholders for a consultative vote. The 2015 Remuneration Report was approved by more than 93% of the shareholders.

In December 2015, the intention to divide the Galenica Group in the fourth quarter of 2016 and transform the two Business units Vifor Pharma and Galenica Santé into two independent, listed companies was announced. It is not currently possible to provide any information on the level of remuneration for the time subsequent to this and particularly in the event that the division of the Business units cannot be implemented as planned in 2016 as a result of unforeseeable circumstances. Due to the provisions of law and the Articles of Association, the maximum possible remuneration of the Board of Directors and Corporate Executive Committee for the business year 2017 was therefore also submitted to the vote of the shareholders, with the same basis being proposed as for the financial year 2016.

The shareholders approved the proposed maximum total remuneration for 2017.

#### **Re-elections to the Board of Directors**

The following members of the Board of Directors were re-elected for a term of office lasting one year: Etienne Jornod as Executive Chairman, and as members of the Board of Directors: This E. Schneider (Vice Chairman), Daniela Bosshardt-Hengartner, Prof. Dr. Michel Burnier, Dr. Romeo Cerutti, Marc de Garidel, Dr. Sylvie Grégoire, Fritz Hirsbrunner and Stefano Pessina.

Dr. Hans Peter Frick (born 1946), member of the Board of Directors since 2010, did not stand for re-election at this year's Annual General Meeting.

#### **Re-elections to the Remuneration Committee**

The following members of the Board of Directors were re-elected to the Remuneration Committee for a term of office lasting one year: Daniela Bosshardt-Hengartner, Prof. Dr. Michel Burnier and This E. Schneider. Following the Annual General Meeting, the Board of Directors appointed Daniela Bosshardt-Hengartner as Chairwoman of the Remuneration Committee.

Date 28 April 2016  
Page 2/2  
Subject 2016 Annual General Meeting of Galenica Ltd.

**Important dates:**

Half-year report 2016	9 August 2016
Annual General Meeting 2017	11 May 2017

**For further information, please contact:**

**Media Relations:**

Christina Hertig, Head Corporate Communications  
Tel. +41 58 852 85 17  
E-mail: [media@galenica.com](mailto:media@galenica.com)

**Investor Relations:**

Julien Vignot, Head Investor Relations  
Tel. +41 58 852 85 29  
E-mail: [investors@galenica.com](mailto:investors@galenica.com)

***Galenica** is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group's income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).*

*For more information, please visit the company's website at [www.galenica.com](http://www.galenica.com).*